SEC Form 4 · accession 0001209191-17-059627
Dimension Therapeutics, Inc. · DMTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John Hohneker
Director
Period of report
Nov 7, 2017
Accepted (ET)
Nov 7, 2017 · 5:07 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001592288
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $4.60 | Nov 7, 2017 | D | 38,000 | D | — | Jan 17, 2027 | Common Stock | 38,000 | 0 | D |
Explanation of responses
- F1This stock option, which vests annually over three years, beginning January 18, 2017, subject to the director's continued service on the Board, was assumed by Ultragenyx Pharmaceutical Inc. ("Ultragenyx"), and converted in accordance with the exchange ratio as set forth in the Agreement and Plan of Merger (the "Merger Agreement"), dated October 2, 2017, between the Issuer, Ultragenyx and Mystic River Merger Sub Inc., a direct, wholly-owned subsidiary of Ultragenyx.